Dishman Carbogen Amcis Limited has informed the Exchange about General Updates
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The company announced that the US FDA inspection at its Naroda, Ahmedabad facility was successfully completed on 12th June 2025. The inspection was concluded without any observations and no Form 483 was issued, meaning the regulator found no compliance concerns. With this, the company's facilities at Naroda and Bavla in India, along with multiple group facilities in Switzerland and the Netherlands, continue to remain US FDA approved. This is a positive regulatory outcome that supports the company's ability to serve US markets without disruption.
Positive for shareholders — a clean US FDA inspection removes regulatory overhang and confirms the company can continue supplying the US market from this facility, supporting business continuity and potential new order wins.